{"analyses":[{"ciLowerLimit":"0.38","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"4.69","estimateComment":"Analysis was based on repeated measures analysis of covariance (ANCOVA) model, including arm, baseline scale score, randomization stratification factors and visit as repeated measure.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Least Squares (LS) Mean Difference","paramValue":"2.53"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.84","value":"-2.76"},{"groupId":"OG001","spread":"14.95","value":"-0.77"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"182"}],"units":"Participants"}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.76","value":"-2.65"},{"groupId":"OG001","spread":"15.59","value":"0.26"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"177"}],"units":"Participants"}],"title":"Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.59","value":"-0.82"},{"groupId":"OG001","spread":"14.62","value":"0.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"title":"Cycle 7 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.59","value":"-1.05"},{"groupId":"OG001","spread":"14.75","value":"2.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"148"}],"units":"Participants"}],"title":"Cycle 9 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.15","value":"-1.89"},{"groupId":"OG001","spread":"15.63","value":"1.06"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"132"}],"units":"Participants"}],"title":"Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.31","value":"-1.55"},{"groupId":"OG001","spread":"18.27","value":"2.11"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"145"}],"units":"Participants"}],"title":"Safety Follow-up"}],"denoms":[{"counts":[{"groupId":"OG000","value":"226"},{"groupId":"OG001","value":"228"}],"units":"Participants"}],"description":"The QLQ-C30 physical function is one of the functional domains of the EORTC QLQ-C30 self-reported instrument and the physical functioning score score ranges from 0-100 points, with 100 points indicating the best possible functioning. A positive change from baseline indicated an improvement in functioning.","dispersionType":"Standard Deviation","groups":[{"description":"Carfilzomib was administered twice-weekly intravenously as a 10 ± 5 minute infusion using an infusion pump on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. The dose was 20 mg/m\\^2 on Days 1 and 2 of Cycle 1 and 27 mg/m\\^2 beginning on Day 8 of Cycle 1 and thereafter. Participants also received lenalidomide 25 mg daily orally on Days 1 to 21 of each cycle and dexamethasone 40 mg weekly orally or intravenously. Participants were treated for up to 12 28-day cycles.","id":"OG000","title":"Twice-weekly KRd 20/27 mg/m^2"},{"description":"Carfilzomib was administered once-weekly intravenously as a 30 ± 5 minute infusion using an infusion pump on Days 1, 8, and 15 of each 28-day cycle. The dose was 20 mg/m\\^2 on Day 1 of Cycle 1 and 56 mg/m\\^2 beginning on Day 8 of Cycle 1 and thereafter. Participants also received lenalidomide 25 mg daily orally on Days 1 to 21 of each cycle and dexamethasone 40 mg weekly orally or intravenously. Participants were treated for up to 12 28-day cycles.","id":"OG001","title":"Once-weekly KRd 20/56 mg/m^2"}],"paramType":"MEAN","populationDescription":"The ITT population included all randomized participants. Participants with data available at each time point are presented. All participants in the overall number of participants analyzed contributed to the data in the endpoint.","reportingStatus":"POSTED","timeFrame":"Baseline (Cycle 1 Day 1), Cycle 3 Day 1, Cycle 5 Day 1, Cycle 7 Day 1, Cycle 9 Day 1, Cycle 12 Day 1, and safety follow-up (30 days after last dose)","title":"Change From Baseline in European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ)-Core 30 (C30) Physical Functioning Scale","type":"SECONDARY","unitOfMeasure":"Score on a scale"}